biological therapy

Summary

Summary: Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.

Top Publications

  1. ncbi Biologic therapies in autoimmune diseases
    Henry Penn
    Department of Rheumatology, Royal Free Hospital, London
    Clin Med 6:105-8. 2006
  2. ncbi Campylobacter bacteriophages and bacteriophage therapy
    P L Connerton
    School of Biosciences, Division of Food Sciences, University of Nottingham, Loughborough Leics, UK
    J Appl Microbiol 111:255-65. 2011
  3. pmc High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria
    Matthew J Hamilton
    Department of Soil, Water and Climate, BioTechnology Institute and Microbial and Plant Genomics Institute, University of Minnesota, St Paul, MN, USA
    Gut Microbes 4:125-35. 2013
  4. pmc Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy
    Anne Bruttin
    Nestle Research Center, Nestec Ltd, Vers chez les Blanc, CH 1000 Lausanne 26, Switzerland
    Antimicrob Agents Chemother 49:2874-8. 2005
  5. pmc Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions
    Julia Garbe
    Institute of Microbiology, Technische Universitat Braunschweig, Spielmannstr, 7, 38106 Braunschweig, Germany
    BMC Microbiol 10:301. 2010
  6. ncbi Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients
    Christina Jorup-Rönström
    Stockholm South General Hospital, Sjukhusbacken 10, Stockholm, Sweden
    Scand J Gastroenterol 47:548-52. 2012
  7. pmc Genome dynamics of Campylobacter jejuni in response to bacteriophage predation
    Andrew E Scott
    Division of Food Sciences, University of Nottingham, Loughborough, United Kingdom
    PLoS Pathog 3:e119. 2007
  8. ncbi Biological therapies for inflammatory bowel diseases
    Paul Rutgeerts
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 136:1182-97. 2009
  9. ncbi Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series
    Timothy A Rubin
    Essentia Health Duluth Clinic Digestive Health Center, Duluth, MN, USA
    Anaerobe 19:22-6. 2013
  10. pmc The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:18. 2011

Detail Information

Publications244 found, 100 shown here

  1. ncbi Biologic therapies in autoimmune diseases
    Henry Penn
    Department of Rheumatology, Royal Free Hospital, London
    Clin Med 6:105-8. 2006
    ..This review briefly summarises the established uses of biologic therapies in rheumatoid disease, and outlines other diseases in rheumatology and other fields where biologic agents are finding a role...
  2. ncbi Campylobacter bacteriophages and bacteriophage therapy
    P L Connerton
    School of Biosciences, Division of Food Sciences, University of Nottingham, Loughborough Leics, UK
    J Appl Microbiol 111:255-65. 2011
    ..The evolutionary consequences of naturally occurring bacteriophage infection that have come to light through investigations of bacteriophages in the poultry ecosystem will also be discussed...
  3. pmc High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria
    Matthew J Hamilton
    Department of Soil, Water and Climate, BioTechnology Institute and Microbial and Plant Genomics Institute, University of Minnesota, St Paul, MN, USA
    Gut Microbes 4:125-35. 2013
    ..Our results demonstrate that frozen fecal microbiota from a healthy donor can be used to effectively treat recurrent CDI resulting in restoration of the structure of gut microbiota and clearing of Clostridum difficile...
  4. pmc Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy
    Anne Bruttin
    Nestle Research Center, Nestec Ltd, Vers chez les Blanc, CH 1000 Lausanne 26, Switzerland
    Antimicrob Agents Chemother 49:2874-8. 2005
    ..This is, to our knowledge, the first safety test in the recent English literature which has measured the bioavailability of oral phage in humans and is thus a first step to the rational evaluation of phage therapy for diarrheal diseases...
  5. pmc Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions
    Julia Garbe
    Institute of Microbiology, Technische Universitat Braunschweig, Spielmannstr, 7, 38106 Braunschweig, Germany
    BMC Microbiol 10:301. 2010
    ..Phage therapy is an alternative to treat these chronic P. aeruginosa infections. However, little is known about the factors which influence phage infection of P. aeruginosa under infection conditions and suitable broad host range phages...
  6. ncbi Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients
    Christina Jorup-Rönström
    Stockholm South General Hospital, Sjukhusbacken 10, Stockholm, Sweden
    Scand J Gastroenterol 47:548-52. 2012
    ..To the best of our knowledge, this is the first time a fecal culture of microbes has retained the possibility for years to cure a substantial number of patients with CDAD...
  7. pmc Genome dynamics of Campylobacter jejuni in response to bacteriophage predation
    Andrew E Scott
    Division of Food Sciences, University of Nottingham, Loughborough, United Kingdom
    PLoS Pathog 3:e119. 2007
    ..jejuni exists in vivo as families of related meta-genomes generated to survive local environmental pressures...
  8. ncbi Biological therapies for inflammatory bowel diseases
    Paul Rutgeerts
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 136:1182-97. 2009
    ..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
  9. ncbi Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series
    Timothy A Rubin
    Essentia Health Duluth Clinic Digestive Health Center, Duluth, MN, USA
    Anaerobe 19:22-6. 2013
    ..difficile infection (RCDI) has become increasingly frequent, and alternative treatments are needed. We examined the efficacy of fecal microbiota transplantation (FMT) instilled into the upper gastrointestinal tract for RCDI...
  10. pmc The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:18. 2011
    The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological ..
  11. ncbi Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)
    M Sánchez-Regaña
    Department of Dermatology, Psoriasis and Phototherapy Center, Hospital Universitari Sagrat Cor, Barcelona, Spain
    J Eur Acad Dermatol Venereol 25:579-86. 2011
    ..Nail psoriasis represents a challenge for specialists. There is no comparative study of systemic treatment's effectiveness at this site...
  12. ncbi Growth factor receptor expression and remodeling of saccular cerebral artery aneurysm walls: implications for biological therapy preventing rupture
    Juhana Frösen
    Neurosurgery Research Group, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Neurosurgery 58:534-41; discussion 534-41. 2006
    ..The receptors regulating SCAA wall remodeling are, however, unknown...
  13. ncbi Biological therapy of inflammatory bowel disease
    Danuta Owczarek
    Department of Gastroenterology and Hepatology, Jagiellonian University, Medical College, Krakow, Poland
    Pol Arch Med Wewn 119:84-8. 2009
    ..commonly fails to bring satisfactory results, therefore an interest in new therapeutic options, that is, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucapheresis, has aroused recently...
  14. ncbi The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 95:340-53. 2002
    ..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
  15. ncbi Fecal microbiota transplantation: techniques, applications, and issues
    Thomas Julius Borody
    Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, New South Wales 2046, Australia
    Gastroenterol Clin North Am 41:781-803. 2012
    ....
  16. ncbi Role of biological therapy for inflammatory bowel disease in developing countries
    Gerhard Rogler
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
    Gut 61:706-12. 2012
    ..If IBD emerges to the same extent in those countries as it has in the West, the need for biological therapy will increase dramatically, and the pharmaceutical industry, healthcare providers, patient advocate groups, ..
  17. ncbi Economical aspect of biological therapy in inflammatory conditions in Hungary
    Judit Laki
    Department of Medical Expertise, Clinical Auditing and Analysis, National Health Insurance Fund Administration, Váci út 73 A, 1139 Budapest, Hungary
    Expert Opin Biol Ther 13:327-37. 2013
    ..All biological agents except rituximab were first line therapies; rituximab was a second line option in rheumatoid arthritis...
  18. pmc Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis
    Milan Buc
    Department of Immunology, Comenius University School of Medicine, 813 72 Bratislava, Slovakia
    Mediators Inflamm 2013:963748. 2013
    ..Furthermore, we discuss how laboratory immunology can offer physicians its help in the diagnosis process and decisions what kind of biological therapy should be used.
  19. ncbi Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy
    R Duarte
    Centro de Referência de Tuberculose Multi resistente da Região Norte
    Acta Reumatol Port 37:253-9. 2012
    ..Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biologic therapy...
  20. ncbi Safety of biologic therapy in rheumatoid arthritis
    Robert S Woodrick
    Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, McGaw M300, Chicago, IL 60611, USA
    Nat Rev Rheumatol 7:639-52. 2011
    ..With careful patient selection and appropriate vigilance on the part of treating physicians and other care providers, these compounds can be safely integrated into the therapeutic plan...
  21. pmc Bacteriophage biocontrol in animals and meat products
    R J Atterbury
    School of Clinical Veterinary Science, University of Bristol, Langford, Bristol BS40 5DU, UK
    Microb Biotechnol 2:601-12. 2009
    ..This review will provide a brief overview of the history of PT in the West and will summarize some of the key findings of phage biocontrol studies in animals and meat products...
  22. ncbi Biological therapies of autoimmune diseases
    Irene S Kourbeti
    Internal Medicine, University Hospital, Medical School, University of Crete, Heraklion, Greece
    Curr Drug Targets Inflamm Allergy 4:41-6. 2005
    ..Susceptibility to infections has always been a major concern; a high level of suspicion is necessary and strategies should be implemented for the prevention, the rapid identification and pre-emptive therapy of such infections...
  23. ncbi Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept
    Jerry Bagel
    Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey 08520, USA
    J Am Acad Dermatol 67:86-92. 2012
    ..Biologic therapies are used to treat moderate to severe psoriasis, but evidence from randomized, controlled studies is lacking regarding scalp-related effectiveness...
  24. ncbi Complete objective response to biological therapy of plurifocal breast carcinoma
    Giuseppe Di Bella
    Di Bella Foundation, Bologna, Italy
    Neuro Endocrinol Lett 29:857-66. 2008
    In this case presentation, a woman with breast carcinoma who chose to try Prof. L. DiBella's biological therapy (MDB), was found, after seven months, to have a 50% reduction in objective measures of her carcinoma and was totally cured ..
  25. ncbi Pharmacokinetic principles of bacteriophage therapy
    Robert J H Payne
    School of Biological Sciences, Royal Holloway, University of London, London, UK
    Clin Pharmacokinet 42:315-25. 2003
    ..Understanding such formulae is important for interpreting data and guiding experimental design. Tailoring pharmacokinetic models for specific systems needs to become standard practice in future studies...
  26. pmc Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection
    Lisa A Carmody
    Department of Pediatrics and Communicable Disease, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    J Infect Dis 201:264-71. 2010
    ..cenocepacia lung infection model. Systemic phage administration was more effective than inhalational administration, suggesting that circulating phages have better access to bacteria in lungs than do topical phages...
  27. ncbi Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network
    Kevin L Winthrop
    Oregon Health and Sciences University, Portland 97239, USA
    Clin Infect Dis 46:1738-40. 2008
    ..Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context...
  28. ncbi Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion
    J M Laparra
    Instituto de Agroquimica y Tecnologia de Alimentos CSIC, Burjassot Valencia, Spain
    J Cell Biochem 109:801-7. 2010
    ..Therefore, bifidobacteria change the gliadin-derived peptide pattern and, thereby, attenuate their pro-inflammatory effects on Caco-2 cells...
  29. ncbi Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations
    Steven Hagens
    EBI Food Safety, Nieuwe Kanaal 7P, 6709 PA Wageningen, The Netherlands
    Curr Pharm Biotechnol 11:58-68. 2010
    ..This review will discuss these issues on the basis of the available literature as well as providing an outlook on the potential of phages in future applications...
  30. ncbi European regulatory conundrum of phage therapy
    Gilbert Verbeken
    Hospital Center of the Base Queen Astrid, Laboratory for Molecular and Cellular Technology, Burn Unit, Bruynstraat 1, B 1120 Neder over Heembeek, Belgium
    Future Microbiol 2:485-91. 2007
    ..As a long-term solution, however, we suggest the creation of a specific section for phage therapy under the Advanced Therapy Medicinal Product Regulation...
  31. ncbi Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model
    Takeaki Matsuda
    Department of Surgery, Weill Medical College of Cornell University, New York, USA
    Surgery 137:639-46. 2005
    ..This may minimize systemic cytokine responses and limit inflammation in bacterial sepsis. We determined the effects of t amber A3 T4 LyD and virulent wild-type (WT) phages on mouse bacterial peritonitis...
  32. ncbi Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report
    S Letkiewicz
    Urological and Andrological Clinic UROGEN, 42 600, Tarnowskie Góry, Poland
    Folia Microbiol (Praha) 54:457-61. 2009
    ....
  33. ncbi Biological therapy update in colorectal cancer
    Steven M Sorscher
    Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA
    Expert Opin Biol Ther 7:509-19. 2007
    ....
  34. ncbi Infectious complications of biological therapy
    Nigil Haroon
    Toronto Western Research Institute, University of Toronto, Ontario, Canada
    Curr Opin Rheumatol 21:397-403. 2009
    Although the remarkable efficacy of biological therapy has resulted in significant success in rheumatic disease management, susceptibility to infections remains a concern...
  35. ncbi The risk of infections with biologic therapies for rheumatoid arthritis
    Daniel E Furst
    University of California Los Angeles, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 39:327-46. 2010
    ..To assess the risk of serious and nonserious bacterial and viral infections associated with the use of biologic therapy (abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab) in patients with rheumatoid arthritis (RA)...
  36. ncbi Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
    D D Rhoads
    Department of Psychiatry, University of Minnesota, Minneapolis, USA
    J Wound Care 18:237-8, 240-3. 2009
    ..This phase 1 trial set out to examine the safety of a bacteriophage-based preparation for difficult-to-treat wounds...
  37. ncbi Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy
    Ronan H Mullan
    St Vincent s University Hospital, Dublin, Ireland
    Arthritis Rheum 56:2919-28. 2007
    ....
  38. ncbi Set a microbe to kill a microbe: drug resistance renews interest in phage therapy
    Paul D Thacker
    JAMA 290:3183-5. 2003
  39. ncbi Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
    D Kirn
    Viral and Genetic Therapy Programme, Imperial College School of Medicine and the Imperial Cancer Research Fund, Hammersmith Hospital, London, UK
    Nat Med 7:781-7. 2001
    ..This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies...
  40. ncbi Biological therapy and nail psoriasis
    Monica Lawry
    Nail Disease Clinic, UC Davis, Department of Dermatology, Sacramento, California 95825, USA
    Dermatol Ther 20:60-7. 2007
    ..b>Biological therapy for psoriasis and psoriatic arthritis is now widely used, and early evidence indicates it may have ..
  41. ncbi Optimal bacteriophage mutation rates for phage therapy
    David T Kysela
    Department of Ecology and Evolutionary Biology, Yale University, P O Box 208106, New Haven, CT 06520 8106, USA
    J Theor Biol 249:411-21. 2007
    ..01). Increases to the mutation rate beyond the optimal value at mutation-selection balance may therefore prove generally undesirable...
  42. pmc Summary of the primer on tumor immunology and the biological therapy of cancer
    Yufeng Li
    Department of Melanoma Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    J Transl Med 7:11. 2009
    The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community"...
  43. ncbi Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directions
    Gaia Schiavon
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 10:3-18. 2010
    ..The evidence of a cross-talk among signaling pathways and the recent advances in understanding biology of this neoplasm have led to the new concept of hormone-biological therapy.
  44. pmc Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium
    Ming Zhao
    AntiCancer, 7917 Ostrow Street, San Diego, CA 92111 3604, USA
    Proc Natl Acad Sci U S A 102:755-60. 2005
    ..This result is in marked contrast to bacteria previously tried for cancer therapy that were confined to necrotic areas of the tumor, which may account, in part, for the strain's unique antitumor efficacy...
  45. ncbi Treatment and management of psoriasis with nail involvement: a focus on biologic therapy
    Richard G Langley
    Queen Elizabeth II Health Sciences Centre, Dalhousie University, 1278 University Avenue, Halifax, Nova Scotia, Canada
    Dermatology 221:29-42. 2010
    ..The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options...
  46. ncbi Soluble cytokine receptors in biological therapy
    Rafael Fernandez-Botran
    Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Expert Opin Biol Ther 2:585-605. 2002
    ..Two current areas of research are the identification of their most promising applications and characterisation of their long-term effects...
  47. pmc Effectiveness of a 'hunter' virus in controlling human immunodeficiency virus type 1 infection
    Gisela Garcia-Ramos
    Department of Biology, University of Kentucky, Lexington, KY 40506, USA
    J Gen Virol 91:2513-23. 2010
    ..This study indicates that hunter viruses may halt the progression of the HIV infection by restoring and sustaining high CD4(+) T-cell levels...
  48. pmc Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice
    Ryohei Watanabe
    Third Department of Surgery, Toho University School of Medicine, Tokyo, Japan
    Antimicrob Agents Chemother 51:446-52. 2007
    ..In conclusion, our findings suggest that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa...
  49. pmc Polymeric human Fc-fusion proteins with modified effector functions
    David N A Mekhaiel
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
    Sci Rep 1:124. 2011
    ..Overall, these findings establish an effective IgG Fc-fusion based polymeric platform with which the therapeutic and vaccination applications of Fc-fusion immune-complexes can now be explored...
  50. ncbi Complications of biological therapy for inflammatory bowel diseases
    Wojciech Blonski
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Curr Opin Gastroenterol 22:30-43. 2006
    ..The purpose of this review is to analyze the complications associated with treatment of inflammatory bowel disease with biologic agents...
  51. ncbi Biological therapy for ulcerative colitis: what is after anti-TNF
    Gionata Fiorino
    IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy
    Curr Drug Targets 12:1433-9. 2011
    ..New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently...
  52. ncbi Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
    Steve H Thorne
    Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
    Expert Opin Biol Ther 4:1307-21. 2004
    ....
  53. ncbi Biological therapy for psoriasis
    Suzanne E Clements
    The Dermatology Centre, The University of Manchester, Hope Hospital, Salford
    Br J Hosp Med (Lond) 67:184-7. 2006
  54. ncbi Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO)
    M L Hetland
    Department of Rheumatology, Copenhagen University Hospitals at Hvidovre, Denmark
    Scand J Rheumatol 34:40-4. 2005
    ..To present from the Danish Database for Biological Therapies in Rheumatology (DANBIO) the frequencies and types of adverse events as well as risk factors during treatment with biological agents in clinical practice...
  55. ncbi Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
    Kristian Reich
    Dermatologikum Hamburg, Hamburg, Germany
    Curr Med Res Opin 24:1237-54. 2008
    ..The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated...
  56. ncbi Safety issues with biological therapies for inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 22:370-6. 2006
    The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance.
  57. ncbi Emerging biological therapies in systemic lupus erythematosus
    G R Mount
    Division of Rheumatology, Department of Medicine, Uniformed Services University, Bethesda, Maryland, USA
    Clin Pharmacol Ther 83:167-71. 2008
    ..Effective treatment must be individualized and is often based on the specific manifestations that are seen in each patient. In a similar manner, prognosis is also dependent on the severity and the specific organ systems involved...
  58. ncbi Rheumatoid arthritis: new developments in biologic therapy
    Annil Mahajan
    Postgraduate Department of General Medicine, Government Medical College, Jammu 180016
    J Indian Med Assoc 104:327-30. 2006
    ..To date combination therapy of methotrexate plus a single biologic has been widely studied with synergistic effect. Etanercept and infliximab are two biologics available in India...
  59. ncbi Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer
    Daniel Albo
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Michael E DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, OCL 112A, Houston, TX 77030, USA
    Surg Oncol Clin N Am 17:357-76, ix. 2008
    ..Although a clear "magic bullet" has yet to emerge, this type of targeted approach offers hope in the management of this dreadful disease. This article offers an update on these promising diagnostic and treatment modalities...
  60. ncbi [Treatment of ANCA-associated vascularitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:922-7. 2007
    ..These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects, few but severe, recently been reported with them...
  61. ncbi Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments
    P C M van de Kerkhof
    Department of Dermatology, University Hospital Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    J Eur Acad Dermatol Venereol 20:639-50. 2006
    ....
  62. ncbi The effect of weight on the efficacy of biologic therapy in patients with psoriasis
    Lily Clark
    Department of Dermatology at Columbia University, New York, New York, USA
    J Am Acad Dermatol 58:443-6. 2008
    ..Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight...
  63. ncbi Biologic therapy in psoriasis
    Alka Dogra
    Department of Dermatology, Venereology and Leprology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
    Indian J Dermatol Venereol Leprol 72:256-64; quiz 265. 2006
  64. ncbi Review article: biological drugs in Crohn's disease
    M A Kamm
    St Mark s Hospital, Harrow, Middlesex, UK
    Aliment Pharmacol Ther 24:80-9. 2006
    ..Screening for tuberculosis (TB) diminishes the rate of TB activation. Biological drugs can offer great therapeutic benefit, but their use must be considered in context...
  65. ncbi Biologic response modifier therapy for psoriatic ocular inflammatory disease
    Nancy Huynh
    Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA
    Ocul Immunol Inflamm 16:89-93. 2008
    ..To evaluate the efficacy and safety of biologic response modifiers (BRMs) in the treatment of patients with psoriatic ocular inflammatory disease...
  66. ncbi [Biotherapies for the treatment of asthma: are they the treatment of the future?]
    A B Tonnel
    Service de Pneumologie et Immunoallergologie, CHRU de Lille 59037 Lille Cedex
    Rev Mal Respir 23:10S44-10S48. 2006
  67. ncbi Biologic therapies in juvenile idiopathic arthritis: why and for whom?
    L J McCann
    Royal Liverpool NHS Trust, Alder Hey, Liverpool
    Acta Reumatol Port 32:15-26. 2007
    ..This article reviews the current biologic treatment options available for children with arthritis and the evidence base that supports their use...
  68. ncbi Biologic therapeutics in the treatment of psoriasis. Part 1: review
    Richard G Langley
    Department of Medicine, Dalhousie University, Halifax, NS, Canada
    J Cutan Med Surg 11:99-122. 2007
    ....
  69. ncbi [Rheumatoid arthritis: current status of therapy]
    Dalila Mrabet El Bahri
    Service de Rhumatologie, Hopital La Rabta, Tunis, Tunisie
    Tunis Med 85:1-8. 2007
    ..It is also essential to assure a strict follow-up in patients under biotherapy to detect adverse events that can be sometimes severe. Thus, the ratio benefit/risk must be evaluated before any biotherapy prescription...
  70. ncbi Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease
    Arthur Barrie
    Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Inflamm Bowel Dis 13:1424-9. 2007
    ..This article reviews the therapeutic experiences of the 2 most widely used anti-TNF neutralizing antibodies, infliximab and adalimumab, for immune-mediated EIM of IBD...
  71. ncbi The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis
    R P Katugampola
    Department of Dermatology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Br J Dermatol 156:945-50. 2007
    ..However, these reports only give limited interpretation of the meaning of Dermatology Life Quality Index (DLQI) scores and provide limited comparison data...
  72. ncbi An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options
    Argentina Leon
    University of Miami, Miller School of Medicine, Miami, FL, USA
    Expert Opin Pharmacother 8:617-32. 2007
    ....
  73. ncbi Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies
    Shani Desilva
    Inflammatory Bowel Disease Clinic, Gastroenterology Training Program, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Rev Gastroenterol Disord 8:109-16. 2008
    ..Emerging data suggest that earlier use of biological therapy is associated with improved clinical outcomes and potential disease-modifying effects...
  74. ncbi Biologic therapies in psoriasis: a new therapeutic approach
    Paolo Gisondi
    Section of Dermatology and Venereology, Department of Biomedical and Surgical Sciences, University of Verona, Piazzale A Stefani 1, 37126, Verona, Italy
    Autoimmun Rev 6:515-9. 2007
    ..Moreover, efficacy can reduce over time. Etanercept is moderately active but has a better safety profile, and can be discontinued and re-used without loss of efficacy. The long term safety of all these agents has not been established...
  75. ncbi International guidelines on access to biologic therapy: why the differences and which is best?
    Chris Deighton
    Derbyshire Royal Infirmary, Department of Rheumatology, Derby, UK
    Nat Clin Pract Rheumatol 4:520-1. 2008
  76. doi COMET's path, and the new biologicals in rheumatoid arthritis
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, Albany, NY 12206, USA
    Lancet 372:347-8. 2008
  77. ncbi Safety of biologic therapy
    Wojciech Blonski
    Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
    Inflamm Bowel Dis 13:769-96. 2007
    ..This is because it has been evaluated in many more trials than has any other biologic agent. In addition, postmarketing experience provides very valuable information about adverse events occurring during treatment with this agent...
  78. ncbi Treatment with biologic therapies and the risk of cancer in patients with IBD
    Livia Biancone
    Università Tor Vergata of Rome, Italy
    Nat Clin Pract Gastroenterol Hepatol 4:78-91. 2007
    ..Multicenter, case-control studies in large populations, with a long-term follow-up are needed to define the outcome of patients with IBD treated with biologic therapies...
  79. ncbi The pitfalls in the development of biologic therapy
    Ravinder N Maini
    Nat Clin Pract Rheumatol 3:1. 2007
  80. ncbi Safety of infliximab and other biologic agents in the inflammatory bowel diseases
    Jagadeshwar G Reddy
    General Internal Medicine, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 35:837-55. 2006
    ..Proper selection of candidates for anti-TNF-alpha therapy is critical in maintaining a proper benefit-to-risk ratio...
  81. ncbi A review of biologic treatments for psoriasis with emphasis on infliximab
    S Pirzada
    Dalhousie University, Halifax, Canada
    Skin Therapy Lett 12:1-4. 2007
    ..Real world experience with this class of drugs is expanding and more new biologics are becoming available...
  82. ncbi Understanding the new clinical landscape for psoriasis: a comparative review of biologics
    Daniel N Sauder
    Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 0900, USA
    J Cutan Med Surg 8:205-12. 2004
    ..Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis...
  83. ncbi [Drug therapy and nutrition therapy of a young patient with Crohn disease]
    Matti Verkasalo
    HUS n lasten ja nuorten sairaala, Lastenklinikka PL 281, 00029 HUS
    Duodecim 119:617-24. 2003
  84. ncbi New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice
    Jeffrey P Callen
    Division of Dermatology, University of Loisville School of Medicine, Louisville, Kentucky 40202, USA
    J Am Acad Dermatol 49:351-6. 2003
  85. ncbi Emerging biological therapies in rheumatoid arthritis
    Xavier Mariette
    Rheumatology Department, INSERM EMI 109, Bicêtre Teaching Hospital, Paris Sud University, Le Kremlin Bicetre, France
    Joint Bone Spine 71:470-4. 2004
    ..One of the challenges for the future is to identify ingenious combinations of biological therapies capable of improving the quality and duration of responses without exacerbating side effects...
  86. ncbi How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 4:S25-33. 2004
    ..Some, or all, of these therapies will likely represent important treatments for Crohn's disease in the future...
  87. ncbi Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:S18-24. 2004
    ..This review discusses the results of controlled clinical trials of anti-TNF agents for Crohn's disease...
  88. ncbi Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    Bruce E Sands
    Gastrointestinal Unit and MGH Inflammatory Bowel Disease Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Rev Gastroenterol Disord 4:S10-7. 2004
    ..Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations...
  89. ncbi Biological therapies in the spondyloarthritides--the current state
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Rheumatology (Oxford) 43:1072-84. 2004
    ..Complicated infections including tuberculosis have been reported. These can largely be prevented by appropriate screening. As it stands now, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  90. ncbi Novel biologic therapies for psoriasis
    Jane Barry
    Adelaide and Meath Hospital Dublin, Incorporating the National Children s Hospital, Tallaght, Dublin 24, Ireland
    Expert Opin Biol Ther 4:975-87. 2004
    ..Infliximab, etanercept, alefacept and efalizumab are considered in detail...
  91. ncbi Biologic agents for the treatment of juvenile rheumatoid arthritis: current status
    Ruy Carrasco
    Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Paediatr Drugs 6:137-46. 2004
    ..Randomized trials are ongoing to better define both the efficacy and safety of these novel treatments for children with JRA and other rheumatic diseases...
  92. ncbi Integrating biologic therapies into a dermatology practice: practical and economic considerations
    Mark Craze
    Texas Dermatology Associates, 5310 Harvest Hill, Suite 260, Dallas, TX 75230, USA
    J Am Acad Dermatol 49:S139-42. 2003
    ..This article provides information needed to guide dermatology practices in practical decisions regarding the use of biologic therapies...
  93. ncbi Preparing dermatology nurses: biologic therapy for psoriasis
    Melodie S Young
    University of Texas, Arlington School of Nursing, USA
    Dermatol Nurs 15:413-6, 419-23; quiz 424. 2003
  94. ncbi Upcoming biologic agents for the treatment of rheumatic diseases
    Joseph C Shanahan
    Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Alabama, USA
    Curr Opin Rheumatol 15:226-36. 2003
    ..This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents...
  95. ncbi Update on the mechanisms and efficacy of biological therapies for psoriasis
    John Koo
    UCSF Psoriasis Treatment Center, Department of Dermatology, University of California, 515 Spruce Street, San Francisco, CA 94118, USA
    J Dermatol Sci 38:75-87. 2005
    ....
  96. ncbi Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004
    Lyn Guenther
    Department of Dermatology, University of Western Ontario, London, Ontario, Canada
    J Cutan Med Surg 8:321-37. 2004
    ..5..
  97. ncbi What are the risks of biologic therapy in rheumatoid arthritis? An update on safety
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Rheumatol Suppl 65:33-8. 2002
    ..At this time, treating physicians must carefully weigh the benefits of these new biologics against their risks, particularly in patients at risk of infection...
  98. ncbi Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
    Boulos Haraoui
    Universite de Montreal, RDU CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Curr Opin Rheumatol 18:96-100. 2006
    ..One of the most common observations made during their use is the development of autoantibodies. The purpose of this paper is to review this phenomenon and its clinical implications...
  99. ncbi Use of prognostic markets to guide biologic therapies for rheumatoid arthritis
    Christopher A D'Arcy
    J Rheumatol 29:2662; author reply 2662-3. 2002
  100. ncbi Cutaneous adverse events of biological therapy for psoriasis: review of the literature
    A M Thielen
    Department of Dermatology, University Hospital, Geneva, Switzerland
    Dermatology 211:209-17. 2005
    ..The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives...
  101. ncbi Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    J Drugs Dermatol 4:544-55. 2005
    ....

Research Grants62

  1. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..for systemic cytotoxic therapy, photodynamic therapy (PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
  2. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2013
    ..for systemic cytotoxic therapy, photodynamic therapy (PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
  3. Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.
    SEOYOUNG CATHERINE KIM; Fiscal Year: 2013
    ..Both Divisions have valuable resources including space, equipment, and knowledgeable faculty including experts in RA research as well as pharmacoepidemiology to help me achieve my goals. ..
  4. Translational Research Cancer Centers Consortium Annual Meeting
    Gregory B Lesinski; Fiscal Year: 2012
    ..Furthermore, it will allow for the opportunity to develop joint clinical trials using new promising biologic agents that will e available to patients in geographic regions with a traditionally high incidence of cancer. ..
  5. Monoclonal Antibody Drug Development for Alzheimer's Disease
    William M Pardridge; Fiscal Year: 2012
    ....
  6. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
    ANNE SEARLS DEGROOT; Fiscal Year: 2013
    ..program is to develop, define, validate and commercialize a novel, first-in-class, safe and effective biological therapy to prevent or treat T1D...
  7. Endoscopic Theranostics System
    Seok H Yun; Fiscal Year: 2010
    ..tract diseases at the microscopic level and can simultaneously perform the tissue-specific and cell-specific biological therapy. In the event that gastrointestinal stem cells are available for use, this system will also be utilized to ..
  8. Randomized observation study of biologic therapy for rheumatoid arthritis
    LARRY W contact MORELAND; Fiscal Year: 2010
    ..CCE studies and biomarker predictions are needed to provide rationale algorithms for biological therapy selection given the extensive array of therapies for treating RA...
  9. Longitudinal Comparative Effectiveness &Safety of Biologics in Autoimmunity
    Jeffrey R Curtis; Fiscal Year: 2013
    ....
  10. Molecular Response and Imaging-based Combination Strategies for Optimal PDT
    Tayyaba Hasan; Fiscal Year: 2013
    ..NMSC on the other hand has many options but the high incidence puts a heavy burden on society in terms of cost and suffering. ..
  11. A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
    NOLAN SIGAL; Fiscal Year: 2012
    ..8 million annual US emergency department visits. The goal of this proposal is to develop and commercialize a novel human biologic capable of inhibiting acute allergic reactions as a treatment for severe allergy disease. ..
  12. Validation of CD6 as a New Target for Treating Multiple Sclerosis
    Feng Lin; Fiscal Year: 2013
    ..This study should validate CD6 as a new target for MS therapy and set the stage for further development of the anti-CD6 mAbs and soluble CD6-Fc protein as novel therapeutic agents for MS patients. ..
  13. Targeting surface-bound IgE as a novel allergy therapeutic
    Ke Zhang; Fiscal Year: 2013
    ..This application is directed at the development of a nove allergy therapeutic that is relevant to the public health. ..
  14. Discovering the Future of Pediatric IBD Care
    Wallace Crandall; Fiscal Year: 2012
    ..Our goal is to bring together a wide range of researchers and patients to develop a research plan for the next 5 years that will result in improved outcomes for these patients. ..
  15. TRAIL Mediated Apoptosis in Renal Cell Carcinoma
    Peter Clark; Fiscal Year: 2009
    ..abstract_text> ..
  16. Postdoctoral Research Training in Biotherapy of Cancer
    David L Bartlett; Fiscal Year: 2013
    ..While this program is relatively new, the feedback from the faculty and trainees has been excellent, and the academic productivity has been significant. ..
  17. UTE MR Imaging of the Cartilaginous Endplate in the Lumbar Spine
    Won C Bae; Fiscal Year: 2013
    ..This is likely to be useful for early intervention in treatment of disc degeneration and selection of patients suitable for biological therapy.
  18. Role of Natural Killer Cells in Myocarditis and Dilated Cardiomyopathy
    Sufey Ong; Fiscal Year: 2013
    ..All together, this research will provide a strong background for a novel and much needed biological therapy for myocarditis.
  19. RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER
    Dong Shin; Fiscal Year: 2001
    ....
  20. The third infections in cancer symposium
    ISSAM INAAM RAAD; Fiscal Year: 2012
    ..There will be special emphasis on novel biological therapy and immunomodulation and future approaches in vaccination...
  21. Cardiac Fibrillation: Mechanisms and Therapy
    James N Weiss; Fiscal Year: 2013
    ..However, despite 50 years of molecular and cellular research, no biological therapy has yet emerged with comparable efficacy to the implantable cardioverter- defibrillator...
  22. TAS::75 0872::TAS SMARTT (11-8470187)
    Thomas VanCott; Fiscal Year: 2013
    ..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
  23. TAS::75 0872::TAS SMARTT (11-8470187)
    Thomas VanCott; Fiscal Year: 2012
    ..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
  24. TAS::75 0872::TAS SMARTT (11-8470187)
    Thomas VanCott; Fiscal Year: 2011
    ..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
  25. MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCER
    Jenny Chang; Fiscal Year: 2002
    ....
  26. Improved influenza A virus vaccines using alpha-Gal epitope modification
    Charles Link; Fiscal Year: 2009
    ..We further propose that vaccines devloped with our adjuvant may also increase the immune response to influenza in the elderly. ..
  27. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 1999
    ..Through this CRC we will expedite research aimed at achieving a better understanding of the biologic basis of this disease and its eventual cure. ..
  28. Biologic therapy of Melanoma and Renal Cell Cancer
    Michael Atkins; Fiscal Year: 2006
    ..abstract_text> ..
  29. CONSTRUCTION OF AN ANTIBODY ENGINEERING LABORATORY
    David Gold; Fiscal Year: 1999
    ..component of a major CMMI initiative to establish a major clinical cancer center program in the area of biological therapy. Indeed, all of the current NCI-funded investigators have awards in areas of biological therapy, primarily ..
  30. GENE THERAPY OF CANCER-IMMUNOLOGICAL APPROACHES
    MICHAEL LOTZE; Fiscal Year: 1993
    ..Collectively this application supports extension of a vigorous, mature program in cancer therapeutics, applying the tools of molecular biology to enhance biologic therapies...
  31. Novel Targeted Therapy for Breast Cancer
    Ginette Serrero; Fiscal Year: 2007
    ..activities will serve as the basis for a Phase II SBIR application as a basis for the development of novel biological therapy for breast cancer. Breast cancer remains one of the top three cancers to affect and cause mortality in women...
  32. Bladder Cancer Prevention by Silibinin
    Rajesh Agarwal; Fiscal Year: 2003
    ..Standard treatment for bladder cancer includes surgery, chemo and radiation therapy, biological therapy, and combinations of these...
  33. IMMUNOLOGICAL BASIS OF SUSCEPTIBILITY TO TUBERCULOSIS
    Samuel Behar; Fiscal Year: 2003
    ..genes that govern it will facilitate a more rational approach to development and use of vaccines, drugs, and biological therapy. An aerosol route of inoculation will be used to infect intact mice that are either inherently resistant or ..
  34. Total Synthesis of Palmerolide A
    SUSANN WINBUSH; Fiscal Year: 2009
    ..Stereo and structural isomers of palmerolide will be evaluated for their biological activity in regard to therapuetic potential as anti-melanoma agents. ..
  35. BRM MONITORING OF PEDIATRIC NEUROBLASTOMA/OSTEOSARCOMA
    Paul Sondel; Fiscal Year: 1991
    ..e., colon, breast and lung adenocarcinomas)...
  36. NEURAL STEM CELLS AND NEURO-ONCOLOGY
    Lawrence Recht; Fiscal Year: 2002
    ..In total these studies are designed to develop unique models which in turn should form a base for new clinical approaches to the therapy of glioma. ..
  37. BIOLOGIC THERAPY RESEARCH CAREER DEVELOPMENT PROGRAM
    John Kirkwood; Fiscal Year: 2000
    ....
  38. Targeting AKT as a novel therapy in pancreatic cancer
    Richard Bold; Fiscal Year: 2007
    ..These results will provide mechanistic as well as pre-clinical data in support of our hypothesis and will allow for the development of novel therapy of human pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  39. THIRD INTERNATIONAL CONGRESS OF THE METASTASIS RES SOC
    Garth Nicolson; Fiscal Year: 1990
    ..Growth Factors and Metastasis (D. Tarin and M. Sporn, chairmen) 5. Cell Differentiation and Biological Therapy of metastases (M. Feldman and G. Heppner, chairmen) 6...
  40. RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAY
    Yuying Tan; Fiscal Year: 2002
    ..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  41. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  42. Discovery of novel fluorescent reporter genes
    Ming Zhao; Fiscal Year: 2004
    ..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
  43. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  44. Imageable tumor-targeting bacteria
    Ming Zhao; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  45. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2007
    ..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
  46. Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
    Hiroyuki Kishimoto; Fiscal Year: 2008
    ..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
  47. Orthotopic models of tumor angiogenesis and blood flow
    Meng Yang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  48. Therapeutic hair follicle-derived neurospheres
    Meng Yang; Fiscal Year: 2007
    ..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
  49. Dual-color tumor-host imaging models
    Meng Yang; Fiscal Year: 2007
    ..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
  50. Lanthanides as Novel Anti-Arthritic Agents
    Christopher Evans; Fiscal Year: 2004
    ..A successful outcome to these studies will have identified the basis for a potential new, very inexpensive anti-rheumatic agent whose mode of action differs from that of existing drugs. ..
  51. Novel Nanostructured Calcium Phosphate for Gene Delivery to Bone
    Christopher Evans; Fiscal Year: 2005
    ..2. To evaluate the ability of nCaP-vector constructs to enhance osteogenic responses in vivo. ..
  52. UVEITIS GENE-EXPRESSION PROFILING
    James Rosenbaum; Fiscal Year: 2008
    ..The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis. ..
  53. CHEMOTACTIC FACTORS IN ANIMAL MODELS OF UVEITIS
    James Rosenbaum; Fiscal Year: 2008
    ..We believe that these aims are novel, innovative, especially suited to the skills and achievements demonstrated by our laboratory, and highly relevant to clarifying the pathogenesis of anterior uveitis. ..
  54. Delivery of Therapeutic Genes to Osteoarthritic Joints
    Christopher Evans; Fiscal Year: 2002
    ....
  55. AAOS/NIH Mulit-Year Research Symposia for 2005-2009
    Christopher Evans; Fiscal Year: 2005
    ....
  56. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004
    ..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..
  57. Anterior Uveal Dendritic Cells
    James Rosenbaum; Fiscal Year: 2004
    ..These studies will clarify the function of the immune system within the eye and may suggest novel therapeutic approaches in the treatment of uveitis. ..
  58. IMMUNOLOGY/MOLECULAR BIOLOGY TRAINING IN OPHTHALMOLOGY
    James Rosenbaum; Fiscal Year: 2007
    ..The quality of the institution, the talents of the specific faculty, the abilities of the applicant pool, and the proven success of the program areadditional strengths of this application. ..